Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

Delayed Quote. Delayed  - 05/31 10:14:59 pm
87.06 USD   +1.44%
05/27 Levi & Korsinsky, LLP Announces the Commencement of an Investigat..
05/27 Pomerantz Law Firm Investigates Claims On Behalf of Investors of ..
05/27 GILEAD SCIENCES : European CHMP Adopts Positive Opinion for Gilead&r..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Gilead 1Q Net Slips 32% On Higher Expenses, Weaker Margins

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 10:54pm CEST

Gilead Sciences Inc. (>> Gilead Sciences, Inc.) first-quarter earnings slid 32% as the biopharmaceutical company reported higher expenses and weaker margins, though adjusted profits improved.

Product sales, which generate the majority of the company's revenue, have been rising steadily in recent quarters. In the latest period, product sales rose 19%. Sales of antiviral products, its dominant revenue stream, increased 18 as HIV drugs Atripla and Truvada saw sales gains of 19% and 13%, respectively.

The company also receives royalties for Tamiflu from Roche Holding AG (RHHBY, ROG.VX). Royalty, contract and other revenue from collaborations were also up 19% last quarter.

Lately, Gilead has been focusing on simplifying HIV therapy, a treatment market that it dominates. In December, U.S. regulators accepted Gilead's new drug application for its Quad combination HIV drug, which analysts view as a potential growth driver. The Food and Drug Administration in February also granted Truvada a priority-review schedule, advancing what could become the first treatment labeled for HIV prevention.

Earlier this year, Gilead bought Pharmasset Inc. for more than $11 billion in a deal expected to accelerate the development of treatments for hepatitis C, a hotly contested market. A key drug candidate it obtained with Pharmasset, GS-7977, suffered a setback in February as a majority of hepatitis-C patients in one arm of a clinical trial had a relapse, raising questions about the drug's potential.

In the latest quarter, Gilead posted a profit of $442 million, or 57 cents a share, down from $651.1 million, or 80 cents a share, a year earlier. Excluding acquisition-related expenses, restructuring and stock-based compensation, earnings rose to 91 cents from 87 cents.

Revenue gained 19% to $2.28 billion.

Analysts polled by Thomson Reuters had expected a profit of 93 cents a share and revenue of $2.2 billion.

Operating margin narrowed to 35.1% from 46.8% as total costs and expenses jumped 45%.

Shares were down 1.4% to $52 after-hours. Through the close, the stock is up 29% since the start of the year.

 
   -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com 

Stocks mentioned in the article : Gilead Sciences, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on GILEAD SCIENCES, INC.
05/31 GILEAD SCIENCES : Breaking down barriers to HIV/Aids treatment – afternoon..
05/27 Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Pos..
05/27 Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Scien..
05/27 GILEAD SCIENCES : European CHMP Adopts Positive Opinion for Gilead’s Epclu..
05/25 GILEAD SCIENCES : Announces Appointment of Kevin Young CBE as Chief Operating Of..
05/25 GILEAD SCIENCES INC : Change in Directors or Principal Officers (form 8-K)
05/25 GILEAD SCIENCES : names Kevin Young as new Chief Operating Officer
05/24DJGILEAD SCIENCES : Names New Operating Chief
05/24 GILEAD SCIENCES : Announces Appointment of Kevin Young CBE as Chief Operating Of..
05/23 GILEAD SCIENCES : Breaking down barriers to HIV/Aids treatment – afternoon..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials